Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.

This study found that one year of finasteride treatment significantly reduced PSA levels and prostate volume in men with elevated PSA and negative prior biopsy, potentially aiding prostate cancer diagnosis.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

In this study, PSA levels were significantly lower among African-American men with higher C-peptide levels and Caucasian men with higher HbA1c levels, suggesting a link between metabolic markers and prostate cancer detection.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.

Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.

This study observed smaller reductions in PSA levels in men under 40 taking finasteride 1mg/day compared to older age groups, without changes in testosterone levels.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study explored a computer simulation method for selecting emulsion compositions in dermatology, finding that the PS biocomplex can be effectively used as an emulsifier or co-emulsifier, which streamlines the development process and reduces experimental demands.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This review re-evaluates the role of Serum Prostate Specific Antigen in prostate cancer diagnosis, suggesting it is most reliable for detecting cancer recurrences after treatment.

This study found that estradiol and other sex steroids reduced the capture of monocytes by human endothelial cells in vitro, potentially inhibiting the formation of atherosclerosis by promoting nCAM polysialylation, which interferes with leukocyte tethering to the vascular endothelium.

This study found that serum PSA levels and %fPSA have limited diagnostic capability in distinguishing prostate cancer, suggesting a need for new, more specific and sensitive markers.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.